Journal Information
Vol. 7. Issue 4.
Pages 241-247 (July - August 2011)
Share
Share
Download PDF
More article options
Vol. 7. Issue 4.
Pages 241-247 (July - August 2011)
Full text access
Economic evaluation of tramadol/paracetamol in the management of pain in patients with osteoarthritis in Spain
Evaluación económica de tramadol/paracetamol en el manejo del dolor en pacientes con osteoartrosis en España
Visits
6771
Javier Vidala, Pere Benitob, Anna Manresac, Domingo Ly-Pend, Enrique Batllee, Francisco J. Blancof, Max Brosag, Diana Nievesg,
Corresponding author
diana.nieves@oblikue.com

Corresponding author. Oblikue Consulting, C/Josep Irla i Bosch, 5–7, 1.ª planta, 08034 Barcelona. Spain.
a Servicio de Reumatología, Hospital General Universitario de Guadalajara, Guadalajara, Spain
b Servicio de Reumatología, Hospital del Mar-IMAS, Barcelona, Spain
c CAP Nou Tarraco, Tarragona, Spain
d Centro de Salud Gandhi, Madrid, Spain
e Servicio de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain
f Servicio de Reumatología, Hospital Universitario A Coruña, A Coruña, Spain
g Oblikue Consulting, Barcelona, Spain
This item has received
Article information
Abstract
Objective

To compare the costs of treating osteoarthritis (OA) pain using combination tramadol/paracetamol tablets, Non-Steroidal Anti-Inflammatory Agents (NSAID) alone or NSAID plus proton pump inhibitors (PPI) from the perspective of the Spanish National Health System.

Methods

A decision-analytical model was constructed to analyze the cost associated with three treatment strategies over 6 months. A cost-minimization approach was used, which considered data related to resource use, medication costs and costs for the treatment of adverse events.

Results

In the base-case analysis, costs for 6 months of treatment of OA pain using tramadol/paracetamol were €232.86, compared with €274.60 for NSAID + PPI and €133.75 for NSAID alone. This provided a savings of €41.74 per patient over 6 months for tramadol/paracetamol compared with NSAID + PPI and a cost increase of €99.11 compared with NSAID alone. When renal adverse events associated with NSAID were considered, tramadol/paracetamol was cost saving compared with all NSAID-based regimens (saving €140.02 vs NSAID alone, €280.86 vs NSAID + PPI).

Conclusion

Based on the results of a theoretical decision-analytic model, the data obtained may suggest that tramadol/paracetamol is cost saving compared with NSAID + PPI for the treatment of OA pain over a period of 6 months. Tramadol/paracetamol is also cost saving compared with treatment with NSAID alone if considering renal adverse events

Keywords:
Cost-minimisation analysis
Tramadol/paracetamol
Non-Steroidal Anti-Inflammatory Agents
Osteoarthritis
Resumen
Objetivo

Comparar el coste del tratamiento del dolor en la osteoartrosis (OA) con tramadol/paracetamol frente a los antiinflamatorios no esteroideos (AINE) solos o en combinación con un inhibidor de la bomba de protones (IBP) desde el punto de vista del Sistema Nacional de Salud de España.

Métodos

Se realizó un modelo analítico de decisiones que evaluó los costes derivados de las tres estrategias de tratamiento durante 6 meses. Se utilizó un análisis de minimización de costes considerando datos referentes al uso de recursos, costes farmacológicos y costes derivados del tratamiento de los acontecimientos adversos (AE) de la medicación.

Resultados

En el análisis del caso base, el coste del tratamiento del dolor de la OA durante 6 meses con tramadol/paracetamol fue de 232,86 €, comparado con 274,60 € con los AINE + IBP y 133,75 € con los AINE solos. Por tanto, el tratamiento con tramadol/paracetamol produce un ahorro de 41,74 € por paciente durante 6 meses respecto a AINE + IBP y un coste adicional de 99,11 € respecto a los AINE solos. Al considerar los AE renales, tramadol/paracetamol produce un ahorro comparado con los tratamientos que contienen AINE (140,02 € respecto de los AINE solos y 280,86 € respecto de los AINE + IBP).

Conclusiones

Basándose en los resultados de un modelo teórico analítico de decisiones, los datos sugieren que tramadol/paracetamol produce ahorros comparado con los AINE + IBP en el tratamiento del dolor de la OA durante 6 meses. Tramadol/paracetamol también produce ahorros comparado con los AINE solos si se consideran los AE renales.

Palabras clave:
Análisis de minimización de costes
Tramadol/paracetamol
Antiinflamatorios no esteroideos
Osteoartrosis
Full text is only aviable in PDF
References
[1.]
Encuesta Nacional de Salud de España, 2006. Ministerio de Sanidad y Consumo [accessed 2010 May 31]. Available from: http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2006/EstadoSaludPorcentaje.pdf.
[2.]
L. Carmona, J. Ballina, R. Gabriel, A. Laffon, EPISER Study Group.
The burden of musculoskeletal diseases in the general population of Spain: results from a national survey.
Ann Rheum Dis, 60 (2001), pp. 1040-1045
[3.]
E. Hunsche, J.V. Chancellor, N. Bruce.
The burden of arthritis and nonsteroidal antiinflammatory treatment. A European literature review.
Pharmacoeconomics, 19 (2001), pp. 1-15
[4.]
M.C. Barron, B.R. Rubin.
Managing osteoarthritic knee pain.
J Am Osteopath Assoc, 10710 (2007), pp. ES21-ES27
[5.]
W. Zhang, R.W. Moskowitz, G. Nuki, S. Abramson, R.D. Altman, N. Arden, et al.
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.
Osteoarthr Cartil, 16 (2008), pp. 137-162
[6.]
L. Hooper, T.J. Brown, R. Elliott, K. Payne, C. Roberts, D. Symmons.
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review.
[7.]
S. Hernández-Díaz, C. Varas-Lorenzo, L.A. García Rodríguez.
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Basic Clin Pharmacol Toxicol, 98 (2006), pp. 266-274
[8.]
P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, C. Patrono.
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
BMJ, 332 (2006), pp. 1302-1308
[9.]
W. Zhang, M. Doherty.
EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology.
Br J Sports Med, 40 (2006), pp. 664-669
[10.]
J. Tornero-Molina, J. Vidal-Fuentes, A. Alonso-Ruiz, C. Acebes-Cachafeiro, L. Arboleya-Rodríguez, J. Calvo-Alen, et al.
Documento de consenso de la Sociedad Española de Reumatología para el uso de opioides en el tratamiento del dolor reumático.
Reumatol Clin, 2 (2006), pp. S50-S54
[11.]
R. Emkey, N. Rosenthal, S.C. Wu, D. Jordan, M. Kamin, CAPSS-114 Study Group.
Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial.
J Rheumatol, 31 (2004), pp. 150-156
[12.]
J.C. Silverfield, M. Kamin, S.C. Wu, N. Rosenthal, CAPSS-105 Study Group.
Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallelgroup, add-on study.
Clin Ther, 24 (2002), pp. 282-297
[13.]
N.R. Rosenthal, J.C. Silverfield, S.C. Wu, D. Jordan, M. Kamin, CAPSS-105 Study Group.
Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population.
J Am Geriatr Soc, 52 (2004), pp. 374-380
[14.]
H. Liedgens, M.J. Nuijten, B.P. Nautrup.
Economic evaluation of tramadol/paracetamol combination tablets for osteoarthritis pain in the Netherlands.
Clin Drug Investig, 25 (2005), pp. 785-802
[15.]
I. Méndez, P. Lázaro, J. Vidal, L. Carreño, A. Montero, L. Samper, et al.
Eficiencia en el manejo de la lumbalgia en atención primaria con tramadol solo o combinado con paracetamol: evaluación de coste/efectividad.
Pharmacoeconomics-SRA, 4 (2008), pp. 137-157
[16.]
K. McClellan, L.J. Scott.
Tramadol/paracetamol.
Drugs, 63 (2003), pp. 1079-1086
[17.]
T. Pincus, G.G. Koch, T. Sokka, J. Lefkowith, F. Wolfe, J.M. Jordan, et al.
A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee.
[18.]
J.P. Case, A.J. Baliunas, J.A. Block.
Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium.
Arch Intern Med, 163 (2003), pp. 169-178
[19.]
Consejo General del Colegio Oficial de Farmacéuticos (CGCOF). Base de datos del medicamento. 2009 [accessed 2010 May 31]. Available from: http://www.portalfarma.com.
[20.]
E-Salud. Base de Datos de Costes Españoles. 2008. Oblikue Consulting [accessed 2010 May 31]. Available from: http://www.oblikue.com/bddcostes/.
[21.]
A. Morrison, D.R. Ramey, J. van Adelsberg, D.J. Watson.
Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension.
Curr Med Res Opin, 23 (2007), pp. 2395-2404
[22.]
W.H. Frishman.
Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema.
Am J Cardiol, 89 (2002), pp. 18D-25D
[23.]
J. Ballina, L. Carmona, A. Laffon, Grupo de Estudio EPISER.
Impacto del consumo de AINE en la población general española. Resultados del estudio EPISER.
Rev Esp Reumatol, 29 (2002), pp. 337-342
[24.]
A. Lanas, M.A. Perez-Aisa, F. Feu, J. Ponce, E. Saperas, S. Santolaria, et al.
A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use.
Am J Gastroenterol, 100 (2005), pp. 1685-1693
[25.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial.Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[26.]
S.R. Ahmad, C. Kortepeter, A. Brinker, M. Chen, J. Beitz.
Renal failure associated with the use of celecoxib and rofecoxib.
Drug Saf, 25 (2002), pp. 537-544
[27.]
T.A. Burke, R.A. Zabinski, D. Pettitt, N. Maniadakis, C.J. Maurath, J.L. Goldstein.
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
Pharmacoeconomics, 19 (2001), pp. 33-47
[28.]
Ministerio de Sanidad y Consumo, 2008. Utilización de antiinflamatorios no esteroides (AINE) en España, 1992-2006 [accessed 2010 May 31]. Available from: http://www.agemed.es/profHumana/observatorio/docs/utilizacionAINE-feb08.pdf.
[29.]
M. Drummond, A. Manca, M. Sculpher.
Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
Int J Technol Assess Health Care, 21 (2005), pp. 165-171
[30.]
A. Briggs, M. Sculpher, K. Claxton.
Decision Modelling for Health Economic Evaluation.
OUP, (2006),
[31.]
L. Liaropoulos, M. Spinthouri, T. Ignatiades, G. Ifandi, F. Katostaras, E. Diamantopoulos.
Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece.
Pharmacoeconomics, 14 (1998), pp. 575-588
[32.]
C. Chevat, B.M. Peña, M.J. Al, F.F. Rutten.
Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.
Pharmacoeconomics, 19 (2001), pp. 17-32
[33.]
R.A. Weideman, K.C. Kelly, C.L. Kelley, B. Cryer.
COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.
Am J Manag Care, 8 (2002), pp. 869-877
[34.]
E. Rahme, H. Nedjar.
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rheumatology (Oxford), 46 (2007), pp. 435-438
[35.]
L. Lizán, S. Magaz, C. Varela, Y. Riesgo.
Análisis de minimización de costes del tratamiento del dolor en la artrosis de rodilla o cadera con paracetamol o inhibidores de la COX-2 (rofecoxib).
Aten Primaria, 34 (2004), pp. 534-540
[36.]
A. Whelton.
Renal aspects of treatment with conventional nonsteroidal antiinflammatory drugs versus cyclooxygenase-2-specific inhibitors.
Am J Med, 110 (2001), pp. 33S-42S
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Download PDF
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?